Results 121 to 130 of about 77,174 (152)

Prognostic significance of walking ability at hospital discharge for overall survival in newly diagnosed glioblastoma: a comparison across six peri-treatment assessments. [PDF]

J Neurooncol
Tokiwa S, Natsume K, Yoshida A, Yonezawa H, Kawamura K, Nakanishi K, Higa N, Hanaya R, Shimodozono M.   +8 more
europepmc   +1 more source

Completion of ≥6 cycles of adjuvant temozolomide is the strongest modifiable prognostic factor in glioblastoma: a 17-year real-world cohort of 319 glioma patients from a single Chinese center. [PDF]

Front Oncol
Liu P, Xiao X, Hu B, Xu K, Liu T, Liu X, Huang H, Pang Q, Lu Z, Qing D, Liang Y, Lin S, Chen H, Lu H.   +13 more
europepmc   +1 more source

Genomic characterization of aggressiveness in pituitary neuroendocrine tumors. [PDF]

Neuro Oncol
Benanteur N, Villa C, Bioletto F, Birtolo MF, De Murat D, Masliah-Planchon J, Gravrand V, Lebib I, Benkhellat M, Boezennec R, Allassonnière S, Letourneur F, Martin Y, Bonnet Serrano F, Jacob J, Calugaru V, Barat M, Dohan A, Arrondeau J, Huillard O, Raffin-Sanson ML, Emile JF, Raverot G, Libé R, Guignat L, Garcia C, Groussin L, Bertagna X, Gaillard S, Bertherat J, Jouinot A, Baussart B, Assié G.   +32 more
europepmc   +1 more source

Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: Complementary post-hoc analysis of the prospective, randomized DIRECTOR trial. [PDF]

Neuro Oncol
Karschnia P, Teske N, Le Rhun E, Wirsching HG, Jakola AS, Roder C, Cahill DP, Vik-Mo EO, Berger MS, Young JS, Wick W, Tabatabai G, Steinbach JP, Suchorska B, Drummond KJ, Bello L, Broekman MLD, Vogelbaum MA, Esquenazi Y, Schnell O, Weller M, Tonn JC.   +21 more
europepmc   +1 more source

CATNON conclusion: Closure on concurrent chemotherapy in IDH mutant grade 3 astrocytoma. [PDF]

Neuro Oncol
Schiff D.
europepmc   +1 more source